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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that involves the selective loss of
the upper and lower motor neurons (MNs). Neuroinflammation has been implicated in the pathogenesis of the
sporadic form of the disease. We earlier developed immune-mediated animal models of ALS and demonstrated
humoral and cellular immune reactions in the nervous system and in the sera of patients and animals. The accumulation
of immunoglobulin G (IgG), an elevated intracellular level of calcium, ultrastructural alterations in the MNs, and activation
of the microglia were noted in the spinal cord of ALS patients. Similar alterations developed in mice inoculated
intraperitoneally with IgG from ALS patients or from an immune-mediated goat model.
Methods: We have now examined whether the intraperitoneal injection of mice with IgG from sporadic ALS patients
or from immunized goats with the homogenate of the anterior horn of the bovine spinal cord is associated
with changes in the pro-inflammatory (TNF-α and IL-6) and anti-inflammatory (IL-10) cytokines in the spinal
cord and serum of the mice. The levels of cytokines were measured by ELISA.
Results: Intraperitoneally administered IgG from the ALS patients induced subclinical signs of MN disease, while the
injection of IgG from immunized goats resulted in a severe respiratory dysfunction and limb paralysis 24 h after the
injections. Significantly increased levels of TNF-α and IL-10 were detected in the spinal cord of the mice injected with
the human ALS IgG. The level of IL-6 increased primarily in the serum. The IgG from the immunized goats induced
highly significant increases in the levels of all three cytokines in the serum and the spinal cord of mice.
Conclusions: Our earlier experiments had proved that when ALS IgG or IgG from immune-mediated animal models
was inoculated into mice, it was taken up in the MNs and had the ability to initiate damage in them. The pathological
process was paralleled by microglia recruitment and activation in the spinal cord. The present experiment revealed that
these forms of IgG cause significant increases in certain cytokine levels locally in the spinal cord and in the serum of
the inoculated mice. These results suggest that IgG directed to the MNs may be an initial element in the damage to
the MNs both in human ALS and in its immune-mediated animal models.
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Background
Amyotrophic lateral sclerosis (ALS) is a progressive neu-
rodegenerative disease which primarily affects the upper
and lower motor neurons (MNs) in the motor cortex,
the brainstem, and the ventral horn of the spinal cord.
Five to ten percent of ALS cases are considered to be fa-
milial (fALS), in which several genes have been found to
be altered [1, 2]. The majority of ALS cases, however,
are sporadic (sALS). Many hypotheses have been put
forward to explain the selective degeneration of the
MNs in ALS, including excitotoxicity [3–6], oxidative
stress [7, 8], cytoskeletal abnormalities [9, 10], and the
aggregation of abnormal proteins [2, 11]. These patho-
genic mechanisms can be accounted in part by the gen-
etic defects in fALS patients.
On the other hand, in sALS, the role of autoimmune
mechanisms is increasingly emphasized [12–14]. The
evidence indicates that the above processes are interre-
lated [6, 15]. Complex interactions between neurons and
their non-neuronal neighbors have been documented in
the pathological processes [13]. Non-neuronal cells con-
tribute significantly to neuronal cell loss, mainly through
neuroinflammatory processes [13, 14]. Glial cells and
cells of the innate and acquired immune system are re-
cruited and become activated. Reactive astrocytes in
ALS can produce pro-inflammatory mediators, including
interleukin-6 (IL-6) [16] and tumor necrosis factor-alpha
(TNF-α) [17, 18].
Microglia accumulation and activation can be ob-
served in close vicinity to MNs in the spinal cord of ALS
patients [19–21]. The most potent antigen-presenting
cell type, the dendritic cells, also appear in the affected
area, and the conditions for local antigen presentation
are therefore given in the central nervous system (CNS)
tissue [19].
Moreover, both CD4+ and CD8+ T cell infiltrations
can be detected in human autopsy spinal cord samples
from ALS patients [21, 22]. The activation of the innate
and humoral immunity was described also in ALS trans-
genic mice [23]. Signs of the activation of the humoral
immune response can also be demonstrated. Immuno-
globulin G (IgG) can be visualized postmortem in the
spinal cord and cortical MNs of ALS patients [24]. IgG
transferred intraperitoneally (ip) from sALS patients to
mice is taken up by MNs [25], induces ultrastructural al-
terations and increases the calcium level in them [26–
28], similarly to the ultrastructural alterations in the
axon terminals from ALS patients in muscle biopsy sam-
ples [29].
Furthermore, sALS IgG that has accumulated in the
cytoplasm of the MNs recruits activated microglia cells
in the vicinity of the MNs [30]. It can also selectively in-
duce the apoptosis of MNs via the caspase-3 pathway
[31]. IgG produced by the immunization goats or guinea
pigs with a ventral horn homogenate of the bovine spinal
cord given ip to mice in another immune-mediated model
of ALS evokes similar increases in intracellular calcium
level and similar ultrastructural signs of MN degeneration
to those induced by sALS IgG [32]. Moreover, it causes se-
vere weakness and death of the recipients. A set of 20
antibodies characteristic of ALS directed to 20 human
protein antigens were recently determined in the sera of
ALS patients with a human protein array [33].
The immune-inflammatory reaction is associated with the
production of neurotoxic cytokines and oxygen radicals in
ALS. Experiments on transgenic mice overexpressing TNF-
α, IL-6, and IL-3 in the CNS have demonstrated that the pri-
mary overexpression of these molecules without any exter-
nal insult is sufficient to cause neurological deficits in vivo
through either indirect or direct action on the MNs [34–36].
Ex vivo human data are also important as regards cyto-
kines in sALS. Circulating levels of TNF-α and its soluble
receptors are increased in the blood [37]. IL-6 [38, 39],
transforming growth factor-beta (TGF-β) [40], IL-17, IL-23
[41], IL-12, and IL-15 [42] are also elevated in the serum
and cerebrospinal fluid (CSF) of patients with ALS.
As opposed to the human diseases, cytokines can be
determined directly in the CNS in animal models of MN
diseases. Detectable TNF-α levels were reported in the
CNS tissue of “mnd” mice (a model for a late-onset MN
dysfunction) when the animals develop neurological
symptoms [43]. Studies on SOD1 transgenic mice and
rats demonstrated increased levels of TNF-α and TGF-β
expression prior to the onset of a motor dysfunction
[44–46]. Experiments on SOD1-mutant mice suggest
that changes in cytokine production precede bulk protein
oxidation and apoptosis gene expression [47].
The aim of the present study was to investigate cytokine
production in mice inoculated ip with IgG from the sera of
ALS patients or with anti-MN IgG from experimental
immune-mediated animal models in order to establish
whether IgG antibody taken up by the MNs is able to initi-
ate changes in cytokine levels in the spinal cord and serum
of the animals within 24 h.
Such detected changes would prove that, besides the
local harmful effect on the MNs, anti-MN IgG can induce
the production of certain cytokines in the spinal cord and
in the serum of the animals, initiating an inflammatory
reaction.
Methods
Patients and goats as sources of IgG and the preparation
of IgG
Blood was obtained by phlebotomy from three sALS pa-
tients: two women and a man. The ages at diagnosis were
51, 55, and 59 years, and the duration of the disease from
the first-noted symptoms was 1.5, 1, and 3 years. All three
patients died, and autopsy samples were examined and
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partly reported on in this work. As controls, a gender and
age-matched normal individual (woman), a woman with
Parkinson’s disease and a man with multifocal motor
neuropathy served as blood donors with their informed
consent. The blood samples from the sALS patients were
obtained within 1 month after establishment of the diag-
nosis. They had readily discernible upper and lower MN
symptoms with bulbar involvement at the time of phlebot-
omy. The clinical diagnosis was established according to
the El Escorial criteria [48] on the basis of medical history,
physical examinations, electromyographic studies, exclu-
sionary clinical, biochemical studies, and imaging tech-
niques performed in order to rule out other diagnostic
considerations. The autopsies demonstrated the patho-
logical and histological signs of ALS and ruled out other
diseases. The experiments were approved by the ethical
committee of the University of Szeged. None of the pa-
tients received immunosuppressive treatment prior to
serum collection. IgG was purified on an Avid/AL TM
column (Bioprobe International, Inc. Tustin, CA, USA)
according to the manufacturer’s instructions.
Induction of experimental autoimmune gray matter
disease (EAGMD) and production of anti-MN IgG
Three male goats were used to raise antibodies by active
immunization. Preimmune sera had been obtained before
the immunization, and the IgG was isolated from them as
above. EAGMD was then induced by inoculation of the
homogenate of the ventral horn of the bovine spinal cords
[49]. Briefly, the goats were injected subcutaneously with a
mixture of the spinal cord ventral horn homogenate and
complete Freund’s adjuvant (1:1 ratio) at 10 sites over the
back of the animals. One month later, the injections were
repeated with a similar mixture, but containing incom-
plete Freund’s adjuvant. The animals were sacrificed under
deep anesthesia 4 weeks later, when severe weakness had
developed in the extremities and their blood was collected.
IgG was purified according to the method listed above
and was stored at −80 °C until used in injecting mice.
Passive transfer experiments
Altogether, 62 mice were involved in the experiment.
Twelve-week-old Balb/c mice were injected (two injec-
tions in 24 h) ip with 10 mg of one or other IgG sample.
ALS group consisted of 3 + 2 + 2 mice inoculated with
separate IgG samples from the three patients to measure
the changes in the cytokine levels. Simultaneously, nine
mice (3 + 3 + 3) were injected for histological examina-
tions. Seven (3 + 2 + 2) mice were inoculated similarly
with IgG from separate goats with EAGMD (goat
group). Nine other mice (3 + 3 + 3) were inoculated with
the same amount of IgG from the three goats for mor-
phological examinations. Nine mice were injected with
IgG from a healthy human individual, with IgG from the
Parkinson disease patient or with IgG from multifocal
motor neuropathy (three animals with each sample) and
were regarded as negative human controls (control
group). Their IgG were also inoculated into three mice
from each individual for morphological tests. As further
negative controls, three mice were inoculated with the
vehicle of the IgG solution and nine mice with the preim-
mune goat IgGs; each goat IgG was injected into three
mice (group 0). The mice in the group injected with anti-
MN IgG were anesthetized near the terminal stage (24 h
after the first injection), and blood samples were taken
from the heart. The mice in the other groups were also
sacrificed 24 h after the first injection. The spinal cords
were removed and frozen immediately to −70 °C. Blood
samples were centrifuged (20 min, 1600g at 4 °C), and the
sera were stored at −70 °C until use. The spinal cord
samples and sera were later processed for enzyme-linked
immunosorbent assay (ELISA). All animal experiments
were performed according to the appropriate institutional
guidelines and governmental laws for animal protection.
Determination of cytokine levels in serum and spinal cord
samples of mice
ELISA was used to detect changes in the levels of all the
pro-inflammatory TNF-α and IL-6 and anti-inflammatory
(IL-10) cytokines in the passive transfer models of ALS in
the mice injected ip with the IgG from the ALS patients
(ALS group) and in the mice injected ip with the IgG from
the goats with EAGMD (goat group). ELISA was also
applied to measure the levels of the above cytokines in the
mice inoculated with the IgG from the normal control
human individual, from the Parkinson disease patient, or
from the patient with multifocal motor neuropathy (con-
trol group). Finally, as control for the group of mice inoc-
ulated with the IgG from the EAGMD goats, the levels of
the same cytokines were measured in mice inoculated
with the IgG from the preimmune goat serum and with
the vehicle of the IgG solution (group 0).
The immunosorbent assay kits of Biosource Inter-
national, Inc. (Biosource, Camarillo, CA, USA) were used
for quantitative determination of the abovementioned cy-
tokines in the serum and spinal cord samples of mice.
Antigen retrieval in spinal cord samples was enhanced by
means of homogenization with ultrasound for 20 s. The
protein contents of the samples were determined by using
the bicinchoninic acid assay (Pierce TM Thermo Scientific
TM, Rockford, IL, USA). The protein contents of the spinal
cord samples were adjusted to 1 mg/ml. The TNF-α, IL-6,
and IL-10 levels in the homogenates were determined with
the ELISA kits according to the manufacturer’s
instructions. Serum and spinal cord samples and appropri-
ate standards were pipetted into wells coated with either a
polyclonal antibody specific for mouse (m)-TNF-α, a
monoclonal antibody specific for (m)-IL-6, or a
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monoclonal antibody specific for (m)-IL-10. After incu-
bation, biotinylated monoclonal secondary antibodies
were added, followed by streptavidin-peroxidase, and
the incubation was repeated. After incubation and
washing, the bound cytokines were visualized by devel-
oping the peroxidase reaction through the addition of
H2O2, and the absorbency of each well was determined
by means of an ELISA reader. Sera from the immunized
goats (EAGMD) and ALS patients were also used as
controls in order to test for antibody cross-reactivity
during the ELISA with human and goat cytokines.
Statistical analysis of the data
One-way ANOVA followed by the Student-Newman-
Keuls test was used for statistical comparison of the data
from four groups of mice (Figs. 1, 2, and 3): the effects
of the IgG from the ALS patients (ALS group) and the
IgG from the paralyzed goats immunized with the hom-
ogenate of the ventral horn of the bovine spinal cord
(goat group) were compared with those on the appropri-
ate control groups: inoculated with IgG from the healthy
human control, from the patient with Parkinson’s disease
or from the multifocal motor neuropathy case (control
Fig. 1 Photographs of the animals and histological pictures of the accumulation of IgG in the spinal MNs of inoculated mice and from human
autopsy samples. a The accumulation of ip administered ALS IgG in the spinal MNs of mice (one is indicated by an arrow) detected by direct
immunohistochemistry with FITC-labeled antibody reacting with human IgG. Fluorescence picture. The bar indicates 30 μm for each picture: (a–c).
b The accumulation in the spinal MN of a mouse of ip inoculated IgG from a goat immunized with the homogenate of the ventral horn of the
bovine spinal cord, visualized with FITC-labeled anti-goat IgG. Direct immunohistochemistry. Both the MNs and the cell processes contain goat
IgG, and the external membrane of the MNs is immunostained (indicated by an arrow). c Slight IgG immunoreactivity in the spinal MNs of mice
(one is indicated by an arrow) after the ip inoculation of normal human IgG. d The mouse on the left was inoculated with IgG obtained from the
deceased sALS patient whose spinal cord is shown in (e). The body posture of the animal appears unusual, reflecting some decrease in muscle
strength, but obvious paresis did not develop. The mouse on the right was completely paralyzed after the ip injection of IgG from a goat with
EAGMD. e Immunohistochemical picture of the ventral horn MNs from the lumbar region of the spinal cord of a patient who died of ALS. IgG
accumulation can be detected in granular form in the cytoplasm of the MNs with peroxidase-labeled anti-human IgG as a dark reaction product.
(One is indicated by the arrow.) The bar represents 60 μm. f The spinal MNs from autopsy sample of the lumbar spinal cord of a patient without
CNS disease exhibits minimal immunostaining for human IgG with the same immunohistochemical reaction as in (e) (arrow)
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group), and that on mice injected with vehicle or preim-
mune goat serum (group 0).
Histological processing
The mice injected with ALS IgG or anti-MN IgG and the
control mice were perfused through the heart under deep
flurane anesthesia with 100 mmol/l phosphate-buffered
saline (PBS) followed by 4 % neutral paraformaldehyde.
The spinal cords were removed and postfixed in the same
fixative by immersion, then kept in 30 % sucrose contain-
ing PBS to prevent the formation of freezing artifacts. The
pieces of the lumbar spinal cords were frozen in 2-methyl-
butane and 20-μm-thick cross-sections were cut in a cryo-
stat. After rinsing in PBS, the non-specific IgG binding
sites were blocked by floating in 5 % rabbit serum (Sigma-
Aldrich) containing PBS. The sections from animals inoc-
ulated with goat IgG were then floated on a rocker for 3 h
in a 1:400 dilution of FITC-labeled anti-goat IgG (whole
molecule) produced in rabbit (Sigma-Aldrich) containing
3 % normal rabbit serum. In sections from animals
injected with human IgG, the specific antibody-binding
sites were blocked in the same way and were incubated
with a 1:400 dilution of anti-human IgG F(ab’)2 highly
cross-adsorbed FITC-labeled antibody produced in rabbit
(Sigma-Aldrich) in the same way as above. After rinsing,
the sections were placed on glass slides, coverslipped, and
examined in a Nikon Optiphot fluorescence microscope.
Samples from control animals served as controls. As
method control, the fluorescence antibody dilutions were
incubated with normal human serum and/or normal goat
Fig. 2 The levels of TNF-α in the spinal cord and serum of the inoculated mice. Upper. Certain levels of TNF-α were noted in the spinal cord of
the mice in group 0 and in control group. However, the level of TNF-α in the spinal cord of the mice injected ip with 10 mg of the IgG from the
ALS patient (ALS group) was significantly higher than in the mice inoculated with the IgG from the human normal and disease controls (control
group), and in the mice inoculated with the vehicle (without IgG) or with preimmune goat IgG (group 0). The level of TNF-α in the spinal cord of
the mice inoculated ip with the IgG from the goats immunized with the homogenate of the ventral horn of the bovine spinal cord (goat group)
was significantly higher than in the other three groups. The significance of the differences is indicated by the horizontal lines. Lower. No TNF-α
was detected in the serum of the animals in group 0, control group, or ALS group, while the serum of the mice in the goat group contained a
high level of TNF-α. The data indicate that the IgG from ALS patients raised the level of TNF-α only in the spinal cord of the injected mice. In every
figure, the columns denote means and the error bars the SD
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serum, the precipitates were then removed by centrifuga-
tion and the supernatants were used for immunostaining.
One-centimeter long pieces of the lumbar spinal cords
obtained from the autopsies on the three ALS patients
and controls were fixed by immersion in 5 % parafor-
maldehyde and were treated for sectioning in a cryostat
as above. Twenty-micrometer sections were cut, rinsed,
blocked by floating in 5 % normal rabbit serum, and then
incubated as above with a 1:400 dilution of peroxidase-
labeled anti-human IgG (whole molecule) produced in
rabbit (Sigma-Aldrich). After rinsing, the sections were
transferred to Fisherbrand Superfrost™ Plus microscope
slides (Fisher Scientific). The immunoreaction was devel-
oped by using an enhanced diaminobenzidine substrate
kit for 15 min (Pierce, Rockford, IL, USA). The sections
were washed in distilled water, dehydrated in a series of
ethanol, cleared in xylene, coverslipped, and examined in
a Nikon Optiphot light microscope. Samples from the
control human spinal cords from autopsy materials from
individuals not suffering from CNS diseases served as
controls. As method control, the peroxidase-labeled anti-
body dilutions were incubated with normal human serum,
the precipitates were next removed by centrifugation and
the supernatants were used for immunostaining.
Results
Behavior of the injected mice
Each of the mice injected ip with the IgG from the ALS
patients developed slightly sluggish movements gener-
ally. This slight, but noticeable deficit is comparable with
the altered ultrastructure and increased calcium content
in the MNs of mice inoculated with IgG from ALS pa-
tients described previously [26]. Nevertheless, obvious
paralysis was not noted. As opposed to this, the mice
injected with the IgG from the EAGMD goats with limb
paralysis developed severe weakness in the limbs and
Fig. 3 The levels of IL-6 in the spinal cord and the serum of the inoculated mice. Upper. There were demonstrable levels of IL-6 in the spinal cord
in group 0 and in control group. The average level of IL-6 was higher in the spinal cord of the mice inoculated ip with 10 mg of ALS IgG, but the
difference was not statistically significant. The average level of IL-6 was statistically significantly elevated in the mice in the goat group (inoculated
with IgG from the serum of the immunized goats). Lower. Mouse IL-6 was not detected in the serum of the mice in group 0 (injected with only
vehicle or preimmune goat serum), and only traces of IL-6 were found in the serum of the mice treated with normal human or disease control
IgG (control group). The treatment with human ALS IgG (ALS group) or with IgG from the immunized goats raised the IL-6 level extremely in the
serum of the inoculated mice
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could not walk at all at the end of the 24-h observational
period (Fig. 1d). The mice injected with the preimmune
IgG from the same goats, or with the IgG from a normal
human individual, from the Parkinson disease patient or
from the patient with multifocal motor neuropathy, or
with vehicle did not appear to exhibit any change in
movement or behavior.
Immunohistochemical examinations of the lumbar spinal
cord of the mice inoculated with the IgG from the sALS
patient or from the goats with EAGMD and the normal
control IgG
FITC-labeled anti-human IgG revealed the accumulation
of the human IgG in the ventral horn MNs of the mice
inoculated ip with the IgG from the sALS patients. The
staining pattern was cytoplasmic, leaving the nucleus
unstained (Fig. 1a). In certain MNs, the staining was en-
hanced in a granular pattern. The IgG of the three ALS
patients all gave similar MN staining patterns. Cells
other than the ventral horn MNs did not seem to be
stained. The lumbar spinal cord of the mice injected ip
with the IgG from the immunized goats exhibited a dif-
ferent staining pattern with FITC-labeled anti-goat IgG.
The goat IgG similarly accumulated in the MNs of the
ventral horn, but the external membranes and processes
of the cells were also heavily stained (Fig. 1b). The IgG
from all three goats gave similar staining patterns. Only
traces of IgG were detected with the same methods in
the mice inoculated ip with the preimmune IgG from
the goats or the IgG from the human controls (Fig. 1c).
Changes in cytokines in the spinal cord and serum of the
inoculated mice
The levels of TNF-α in the spinal cord of the animals in-
oculated with the preimmune goat IgG or with vehicle
(group 0) were similar to those in the animals inoculated
with the IgG from the normal human individual, from
the Parkinson patient or from the patient with multifocal
motor neuropathy (control group): 56 ± 12.78 pg/ml and
54.2 ± 8.12 pg/ml (means ± SD). The level of TNF-α in
the animals injected with ALS IgG (ALS group) rose to
92.4 ± 14.38 pg/ml, and that in the mice injected with
EAGMD IgG (goat group) to 128.4 ± 8.76 pg/ml. Mean-
while, there was no measurable TNF-α in the serum of
the mice in group 0, control group, or ALS group (inocu-
lation with the IgG from the ALS patients). The IgG of
the goats with EAGMD induced a significant increase in
the level of TNF-α in the serum of the inoculated mice,
albeit it was less than that in the spinal cord (Fig. 2).
The spinal cord level of IL-6 was 12.6 ± 0.658 pg/ml in
group 0 and 9.5 ± 1.53 pg/ml in control group. It was
higher, but not statistically significant in the ALS-IgG
treated animals (15.6 ± 2.878 pg/ml). In contrast, the IgG
from the EAGMD goats raised the IL-6 level significantly
in the spinal cord of the injected mice (38.6 ± 9.378 pg/
ml). The IL-6 level was increased significantly in the
serum of the mice injected either with ALS IgG or with
the IgG from the immunized goats (1528.34 ± 29.36 and
1543.62 ± 12.36 pg/ml). The serum of group 0 did not re-
veal IL-6, while that group of the control contained only
traces of mouse IL-6 (Fig. 3).
IL-10 was also demonstrable in the spinal cord of
group 0 (117 ± 29.4 pg/ml) and control (123 ± 30.6 pg/
ml). On the other hand, there was a 3–4-fold increase in
the spinal cord after treatment with the IgG from the
ALS patients (378 ± 173.6 pg/ml) or the immunized
goats (473.8 ± 138 pg/ml). The serum in group 0 and
control group contained only traces of mouse IL-10. The
serum of the mice after inoculation with the ALS IgG
contained 144.28 ± 82.12 pg/ml IL-10, which was a little
less than one third of the spinal cord level. The level of
IL-10 in the serum of the mice treated with the IgG
from the immunized goats was 827.86 ± 390 pg/ml,
which is higher than that in the spinal cord (473.8 ±
138 pg/ml) (Fig. 4). TNF-α was increased significantly in
the spinal cord of the mice injected with the sALS IgG
or the IgG from the immunized goats with EAGMD
[ANOVA F(3,22) = 62.5, p < 0.0001]. However, an in-
crease in the serum TNF-α level occurred only in the
mice injected with the IgG from the goats with EAGMD
[ANOVA F(3,22) = 13.4, p < 0.0001]. The other possible
neurotoxic cytokine, IL-6, was increased significantly in
the spinal cord of the mice injected with the IgG from
the goats with EAGMD, but not after the sALS IgG
[ANOVA F(3,22) = 44.0, p < 0.0001. Highly significant in-
creases in IL-6 levels were noted in the serum of the mice
injected with either sALS IgG or the IgG from the goats
with EAGMD [ANOVA F(3,22) = 16996.4, p < 0.0001].
The levels of the anti-inflammatory cytokine IL-10 in
the spinal cord of the mice injected with the IgG from
the sALS patients or with the IgG from the goats with
EAGMD were also elevated [F(3,22) = 15.4, p < 0.0001],
and they were also enhanced in the serum [ANOVA
F(3,22) = 23.5, p < 0.0001].
None of the inoculated goat and human IgG-s con-
tained mouse TNF-α, IL-6, or IL-10.
Immunohistochemical examinations of the lumbar spinal
cord of the deceased ALS patients and age-matched
controls who died of non-neurological diseases
Immunostaining for IgG with peroxidase-labeled anti-
bodies demonstrated that most of the MNs in the lum-
bar spinal cord of all three sALS patients contained IgG
in the cytoplasm. The dark, mostly granular reaction
product accumulated mainly in the rough endoplasmic
reticulum, indicating that this is the main target for anti-
body binding (Fig. 1e). The MNs in the ventral horns of
the lumbar spinal cord exhibited no or very little dark
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immunostaining and not in a granular manner, indicat-
ing that IgG did not accumulate in the cells (Fig. 1f ).
Discussion
Our main purpose was to investigate whether the uptake
of ALS IgG or anti-motoneuron IgG can initiate a further
event in the supposed inflammatory reaction in the spinal
cord of the injected mice at the very beginning of the
injury of the motor neurons. We expect that this event is
the initiation of the production of pro-inflammatory cyto-
kines in the spinal cord after the intra-motoneuronal ac-
cumulation of ALS specific IgG. We already proved that
macrophage chemoattractant protein-1 is highly elevated
in the spinal cord of ALS patients (Ref. 19). Therefore, we
investigated the appearance of the most important pro-
and anti-inflammatory cytokines, such as TNF-α, IL-6,
and IL-10. The reasons why we chose these three cyto-
kines are the following: TNF-α and IL-6 play an important
role in orchestrating and influencing the induction of the
cytokine cascade, initiating an inflammatory reaction, and
affecting the production of further cytokines. We also
wanted to know whether any sign of anti-inflammatory re-
action can also be shown, because in these acute passive
transfer experiments, ALS IgG does not cause the death
of spinal MNs, only the initial morphological and electro-
physiological alterations of the degeneration were noted.
That was the reasoning behind choosing IL-10.
The inoculation of ALS and anti-MN IgG from
EAGMD goats induced different changes in the levels of
cytokines in the serum and in the spinal cord in the vari-
ous mouse groups. The spinal cords of the mice in
group 0 and control group (not treated with the ALS
IgG or the IgG from the goats with EAGMD) contained
more TNF-α as compared with the serum. The adminis-
tration of the sALS IgG increased the level of TNF-α in
the spinal cord significantly, but not the serum content.
The IgG from the paralyzed goats elevated the level of
TNF-α in the spinal cord of the injected mice more
(these mice also became paralyzed), but the level of
TNF-α in the serum reached only about half of the
Fig. 4 The levels of IL-10 in the spinal cord and serum of the inoculated mice. Upper. The levels of IL-10 in the spinal cord of the mice in group 0
and control group were almost the same. The spinal cord of the mice inoculated with the IgG from the ALS patients (ALS group) or from the immunized
goats with EAGMD (goat group) contained highly increased levels of IL-10. Lower. IL-10 was not detected in the serum of the mice in group 0 or control
group. The serum of the animals in the ALS group and even more so in the goat group contained significantly higher levels of IL-10
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concentration measured in the spinal cord. These results
indicate that the primary site of the elevation of TNF-α
caused by the sALS IgG or the IgG from the immunized
goats is the spinal cord. In both experimental paradigms,
IgG is known to accumulate in the spinal cord MNs
[25, 32], and signaling for the enhancement of TNF-α
is presumably initiated by the IgG accumulation there,
though the pathway is unknown. TNF-α is mainly
produced by the microglia, but the astrocytes and in-
jured neurons can also secrete this cytokine [18, 50].
Previous passive transfer experiments with IgG from
sALS given ip to mice revealed that microglia were
recruited in the vicinity of MNs filled with sALS IgG
[30]. TNF-α has been shown to potentiate glutamate-
mediated cytotoxicity by two complementary mechanisms:
indirectly by inhibiting glutamate transport to the astro-
cytes and directly by rapidly triggering the surface expres-
sion of calcium-permeable AMPA receptors and NMDA
receptors, while decreasing inhibitory GABAA receptors
on the neurons [6]. TNF-α additionally induces oxidative
stress, and is therefore able to interconnect all of the impli-
cated pathomechanisms in ALS [6].
The IL-6 level was significantly increased in the spinal
cord of the mice inoculated with the IgG from the im-
munized goats (approximately three times higher than in
the other groups), whereas it was approximately 40
times higher in the serum than in the spinal cord after
treatment with the IgG from the goats with EAGMD
and approximately 100 times higher after the inoculation
of the sALS IgG (Fig. 3). These results suggest that the
increase in the level of IL-6 is mostly induced by the
general and systemic effects of sALS IgG and IgG from
the goats with EAGMD on the whole organism, and not
primarily in the spinal cord.
Astroglia isolated from postmortem tissue of both
fALS and sALS patients have been shown to be toxic to
MNs [51]. Reactive astrocytes can secrete increased
amounts of IL-6 and TNF-α, and the TGF-β level has
been found to be elevated in the CSF of sALS patients;
the observed elevations may originate in part from these
cells besides activated T lymphocytes. Another source of
IL-6 is the classically activated microglia. Microglia be-
longing in the M1 group are neurotoxic and produce
pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12,
and IL-23) and reactive oxygen species [52]. Moreover,
during the rapidly progressing phase of the disease
process, cytotoxic CD4+ and CD25− T lymphocytes
(Teffs) proliferate in ALS. This corroborates findings on
ALS mice [53]. Another subset of T cells, Th17, that
produce IL-17 has also been suggested to be crucial in
MN destruction in ALS [54]. IL-6, a secondary cytokine,
is involved in the differentiation, maintenance, and
stabilization of Th17 cells [55] and Th2 lymphocytes
[56]. Th2 cell differentiation is induced through the
expression of IL-4 and the suppression of γ-IFN [57, 58].
IL-6 also inhibits the differentiation of naive CD4+ T
cells into Treg lymphocytes [56]. The suppression of
Treg cell differentiation and the induction of Th17 lym-
phocytes are mediated by IL-6 trans-signaling, since the
IL-6 soluble receptor is necessary for these effects [59].
The lack of lymphocyte recruitment previously demon-
strated in the ALS IgG-injected group [30] is supported
by the fact that only a slight, non-significant elevation
was observed in the level of spinal cord IL-6 in our
present experiments. As a secondary cytokine respon-
sible for enhancing the innate immune response and
promoting the development of Th2 and Th17 lympho-
cytes, IL-6 seems to be important in this process. Be-
cause of the insufficient signals during the short time
scale of passive transfer models, lymphocytes might not
become activated, whereas in ALS patients, where IL-6
and other secondary cytokines have been detected in the
CSF and serum, the immune system can be activated to
its full extent. The elevation of IL-6 observed in the
serum of the sALS-IgG-injected mice suggests that the
involvement of further components of the immune re-
sponse is encouraged systemically.
Endothelial cells might also contribute to the high levels
of IL-6 observed in the serum. Further involvement of the
surrounding cells can occur especially in the case of the
mice injected with the IgG from the immunized goats,
when the animals are in a state of acute distress, with pro-
gressive limb paralysis and insufficient respiration due to
the weakness of the striated muscles. As in infection-
induced inflammation, the endothelial cells may secrete
increased amounts of IL-6, which can exaggerate inflam-
mation through trans-signaling mechanisms [56].
IL-10 was demonstrable in the spinal cord in all the
groups of mice, even in group 0 and control group. The
level of IL-10 was elevated significantly in the spinal
cord of the sALS IgG-inoculated mice, but the increase
in the serum did not attain statistical significance. In
contrast, concordant and significant elevations were ob-
served in both the spinal cord and the serum of the mice
injected with the IgG from the immunized goats. IL-10
is an anti-inflammatory cytokine, and the fact that ALS
IgG induces a comparably higher elevation in the spinal
cord, therefore suggests that, although there is a simul-
taneous anti-inflammatory reaction, it primarily starts in
the spinal cord. In the mice inoculated with the IgG
from the immunized goats, the IL-10 levels in both the
spinal cord and the serum were higher than in the ALS
IgG-injected mice, but the serum contained more IL-10
than the spinal cord. The simultaneous production of
the anti-inflammatory cytokine IL-10 is presumed to
hinder inflammation here too. However, this mechanism
seems to be more effective in the ALS IgG-inoculated
mice, where IL-10 is present in a higher level in the
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spinal cord than in the serum. This may be one of the
reasons why ALS IgG, despite the initiated inflamma-
tion, does not lead to the paralysis of the injected mice.
Another possible reason might be that the inoculated
IgG binds to different antigens. ALS IgG has been
shown to be bound only to intracellular antigens [25],
whereas IgG from EAMND is bound to both intracellu-
lar and external cell membrane antigens [49].
The levels of all three examined cytokines were ele-
vated by the ip injection of the IgG from the ALS pa-
tients or from an autoimmune animal model of ALS
(EAGMD). We established earlier that the specific IgG
antibodies characteristic of the serum of ALS patients
are directed against human proteins mostly found in the
MNs [33]. However, it is not known which are respon-
sible for the alterations of the ultrastructure, calcium
homeostasis, physiological abnormalities of the MNs,
and the increased levels of cytokines. The serum of im-
munized goats was not subjected to such an evaluation.
On the other hand, all of the alterations mentioned
above developed after the ip administration of IgG to
mice, similarly to the effects of ALS IgG. This suggests
that the primary insult to the MNs may also attribute to
the possible effect of autoimmune IgG.
The innate immune response that takes place in the
CNS during acute systemic infection and acute trauma
is unlikely to be detrimental to the brain. On a short
time scale, neurotrophic factors and other molecules are
produced that have important roles in brain homeosta-
sis, neuroprotection, and repair. However, when the
infection or insult becomes chronic or severe, e.g., in
neurodegeneration such as ALS, the delicate balance be-
tween the pro- and anti-inflammatory mechanisms is
disrupted. In the pathology of ALS, as the disease pro-
gresses, the astrocytes and microglia transform from
neuroprotective (M2) to neurotoxic (M1), humoral anti-
bodies are deposited, and activated T cells accumulate,
as do “AbA cells”, aberrant astrocytes in SOD1 mutant
rats [60]. M2 microglia secrete anti-inflammatory cyto-
kines (IL-10) and neurotrophins (NGF, BDNF and IGF-
1). In fALS mouse models, an M2 microglia response
predominates at the beginning of the disease, followed
by M1 neurotoxic signals toward the terminal stages
[61]. The published data indicate that the microglia in-
duces MN death via pro-inflammatory mechanisms
through NF-kB signaling [62].
Conclusions
In previous, well-characterized, immune-mediated models
of sALS [63], and specific immunological reactions were
detected in and around the perikarya of the spinal cord
MNs and also in the axon terminals. These findings cor-
respond with data obtained from ALS autopsy and biopsy
samples [19, 24, 29]. Cytokine production, presumably
following these inflammatory responses, has not been in-
vestigated in immune-mediated, passive transfer models.
Our present experiments revealed characteristic changes
in the levels of pro-inflammatory cytokines TNF-α, IL-6,
and anti-inflammatory cytokine IL-10 both in the spinal
cord and in the serum of mice injected ip with the IgG
from the sALS patients or IgG from goats immunized
with the homogenate of the ventral horn of the bovine
spinal cord. Additional data emerged concerning the
pathomechanism of MN injury simply the uptake of
autoimmune IgG directed to the constituents of MNs is
sufficient to initiate an autoimmune reaction causing ul-
trastructural alterations, dysregulated calcium homeostasis
of the MNs, activation and recruitment of the microglia in
the vicinity of the MNs, and the elevation of pro- and
anti-inflammatory cytokines.
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